UK cuts clinical trial setup times, boosting patient access and life sciences

Traders Union
All News
Geopolitics & Trade
UK cuts clinical trial times

Highlights

UK shortens average commercial trial setup time to 100 days in Q1 2024 from 153 days a year earlier, with all 24 trials launched within 150 days.
Government’s Life Sciences Sector Plan attracts over £3 billion in new public-private investment in the first year, highlighting faster trials as key to global competitiveness.
New initiatives like the cancer trials accelerator and streamlined regulatory pathways aim to make the NHS the preferred partner for cancer clinical trials and innovation adoption.

Trial setup target met ahead of broader rollout

As reported by GOV.UK, the average setup time for commercial trials in the UK falls to 100 days in the three months to March this year, from 153 days in the same period last year, with all 24 commercial trials in that period launched within 150 days.

The government says this exceeds the target in the Life Sciences Sector Plan for 95% of commercial trials to be set up within 150 days. It also says 100% of studies receiving combined MHRA and REC approval in September 2026 do so within 60 days, pointing to faster regulatory and operational timelines across the system.

Examples include the BEATRIX study, which offers pregnant women a government-backed vaccine against group B streptococcus to help prevent infant deaths and stillbirths, reaching reality in less than 150 days. The CHILL study screens its first participant 113 days after entering setup, while Moderna’s Nova 301 study recruits 2,500 volunteers in nine weeks.

Health Innovation Minister James Frith says meeting the target is crucial because it means more patients receive cutting-edge care sooner. Professor Lucy Chappell, chief executive of the National Institute for Health and Care Research and chief scientific adviser at the Department of Health and Social Care, says faster study setup gives patients earlier access to promising new treatments.

Life sciences and NHS gain from faster research delivery

The faster pace comes as the government pushes to strengthen the UK’s position in life sciences, saying more than £3 billion in new public-private investment is attracted during the first year of the plan. Officials present the shorter timelines as a way to ease pressure on the NHS while making the country a more competitive destination for commercial research.

Last week, the Prime Minister sets out four steps intended to give people living with brain cancer a faster route from research to treatment after meeting Archie Goodburn and the Health and Social Care Secretary. The government also says a new cancer trials accelerator will aim to make the NHS the first-choice partner for cancer clinical trials, building on the Cancer Vaccine Launch Pad and the Vaccine Innovation Pathway.

Through the NIHR Industry Hub and a UK-wide network of Commercial Research Delivery Centres, the research system is being reshaped to simplify access for sponsors seeking to run studies in the UK. Steve Bates, executive chair of the Office for Life Sciences, and Lawrence Tallon, chief executive of the Medicines and Healthcare products Regulatory Agency, say a quicker and more predictable trials environment is central to attracting innovation and helping patients access new treatments sooner.

Our earlier article on the UK’s nuclear fusion push highlighted warnings from the UK Atomic Energy Authority that Britain is in an intensifying race with China to commercialise fusion, with supply chains and energy security becoming strategic priorities. We also covered recent technical progress—such as advances in superconducting magnets and improved performance in the Mast Upgrade machine—alongside plans to deliver a prototype fusion power plant by 2040 at West Burton.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.